# Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

> **NCT00135629** · PHASE3 · COMPLETED · sponsor: **Imperial College London** · enrollment: 18 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **BIOLOGICAL:** Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
- **OTHER:** Placebo Injection
- **PROCEDURE:** Venepuncture: 100ml blood sample taken on 12 separate visits

## Key facts

- **NCT ID:** NCT00135629
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135629, "Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00135629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*